The IC50 values for each compound were determined and compared to those of SB225002, a CXCR1/2 competitive inhibitor already tested for its effect on the growth of RCC tumor 12, and used as a reference compound; the results are listed in Table 2. This evidence concerns the gene CXCR1 and neoplasm.